WallStSmart

McEwen Mining Inc. (MUX)vsVersamet Royalties Corporation Common Stock (VMET)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

McEwen Mining Inc. generates 468% more annual revenue ($197.55M vs $34.76M). VMET leads profitability with a 58.5% profit margin vs 17.4%. MUX trades at a lower P/E of 21.3x. VMET earns a higher WallStSmart Score of 45/100 (D+).

MUX

Hold

45

out of 100

Grade: D+

Growth: 8.0Profit: 4.0Value: 5.3Quality: 5.0

VMET

Hold

45

out of 100

Grade: D+

Growth: 8.0Profit: 8.0Value: 4.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MUX2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
92.8%10/10

Revenue surging 92.8% year-over-year

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

VMET3 strengths · Avg: 10.0/10
Profit MarginProfitability
58.5%10/10

Keeps 59 of every $100 in revenue as profit

Operating MarginProfitability
135.6%10/10

Strong operational efficiency at 135.6%

Revenue GrowthGrowth
465.2%10/10

Revenue surging 465.2% year-over-year

Areas to Watch

MUX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.50B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
6.6%3/10

ROE of 6.6% — below average capital efficiency

Free Cash FlowQuality
$-2.45M2/10

Negative free cash flow — burning cash

VMET3 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.32B3/10

Smaller company, higher risk/reward

P/E RatioValuation
58.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : MUX

The strongest argument for MUX centers on Revenue Growth, Price/Book. Profitability is solid with margins at 17.4% and operating margin at -8.9%. Revenue growth of 92.8% demonstrates continued momentum.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.5% and operating margin at 135.6%. Revenue growth of 465.2% demonstrates continued momentum.

Bear Case : MUX

The primary concerns for MUX are EPS Growth, Market Cap, Return on Equity.

Bear Case : VMET

The primary concerns for VMET are EPS Growth, Market Cap, P/E Ratio. A P/E of 58.0x leaves little room for execution misses.

Key Dynamics to Monitor

VMET is growing revenue faster at 465.2% — sustainability is the question.

VMET generates stronger free cash flow (10M), providing more financial flexibility.

Monitor OTHER PRECIOUS METALS & MINING industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MUX scores higher overall (45/100 vs 45/100), backed by strong 17.4% margins and 92.8% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

McEwen Mining Inc.

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

McEwen Mining Inc. is engaged in the exploration, development, production and sale of gold and silver deposits in the United States, Canada, Mexico and Argentina. The company is headquartered in Toronto, Canada.

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company focused on developing novel therapeutics for serious and life-threatening diseases, particularly through its innovative drug development platform that leverages its proprietary metalloenzyme-based technology. The company aims to address unmet medical needs in areas such as fungal infections and oncology, positioning itself at the forefront of therapeutic innovation. Viamet's strategic partnerships and strong intellectual property portfolio underscore its commitment to advancing its pipeline while maximizing shareholder value. As it progresses through clinical development phases, VMET stands to play a significant role in transforming treatment paradigms within its targeted therapeutic areas.

Want to dig deeper into these stocks?